Byron Lee Anderson

US Patent:

52832384, Feb 1, 1994

Filed:

Apr 24, 1992

Appl. No.:

7/874263

Inventors:

Lawrence A. Potempa - Deerfield IL
John J. Kresl - Evanston IL
Byron E. Anderson - Morton Grove IL

Assignee:

Immtech International, Inc. - Evanston IL
Northwestern University - Evanston IL

International Classification:

A61K 3702

US Classification:

514 12

Abstract:

The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP"). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.

US Patent:

59324830, Aug 3, 1999

Filed:

Apr 5, 1996

Appl. No.:

8/628383

Inventors:

Michael A. Baumann - Grayslake IL
Byron E. Anderson - Morton Grove IL
Jonathan P. Fryer - Chicago IL

Assignee:

Northwestern University - Evanston IL

International Classification:

G01N 33564

US Classification:

436507

Abstract:

The invention provides a fragment of C1q which is characterized in that a plurality of such fragments selectively binds immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. The invention also provides a synthetic peptide comprising the sequence: Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala Thr 1 5 10 �SEQ ID NO 2! or variants thereof capable of binding immunoglobulin. Like the C1q fragment, a plurality of the peptides can selectively bind immune complexes or aggregated immunoglobulins in the presence of monomeric immunoglobulin. As a result of this property, the fragments and peptides are well-adapted for removing immune complexes and aggregated immunoglobulins from fluids containing monomeric immunoglobulin, and for detecting or quantitating immune complexes in such fluids. The invention also provides a binding material for removing immune complexes or aggregated immunoglobulins from a fluid. The binding material comprises plural binding peptides, the peptides being characterized in that a plurality of them selectively binds immune complexes and aggregated immunoglobulins in the presence of monomeric immunoglobulin.

US Patent:

54749042, Dec 12, 1995

Filed:

Nov 9, 1993

Appl. No.:

8/149663

Inventors:

Lawrence A. Potempa - Deerfield IL
John J. Kresl - Evanston IL
Byron E. Anderson - Morton Grove IL

International Classification:

G01N 33534
G01N 33574
G01N 3358
A61K 3516

US Classification:

435 723

Abstract:

The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP"). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.

US Patent:

55938973, Jan 14, 1997

Filed:

Jul 6, 1994

Appl. No.:

8/271137

Inventors:

Lawrence A. Potempa - Deerfield IL
Byron E. Anderson - Morton Grove IL

Assignee:

Northwestern University - Evanson IL

International Classification:

G01N 33564
G01N 33543
G01N 3353
A61M 138

US Classification:

436507

Abstract:

A method of binding aggregated immunoglobulin or immune complexes comprising contacting them with modified forms of C-reactive protein. The method may be employed for diagnostic and therapeutic purposes and to deplete fluids of aggregated immunoglobulin or immune complexes. Further, a method of reducing the levels of immune complexes in a mammal comprising administering modified-CRP to the mammal, and a method of binding immunoglobulins comprising contacting them with modified C-reactive protein. Also, a method of binding aggregated immunoglobulin or immune complexes comprising contacting them with antibody to neo-CRP, and a method of modifying C-reactive protein. Finally, a test kit for detecting or quantitating immune complexes and a device for removing aggregated immunoglobulin or immune complexes from fluids are disclosed.